Drug-labels.com

Hypertet: Uses, Side Effects and Dosage

Updated:
Strength:
250 UNIT
Active ingredient:

Patient Medication Information: uses, side effects, how to take - Hypertet

What is HyperTET®used for?

HyperTET® is used to prevent tetanus in people who may have been exposed to the bacteria that causes tetanus from an injury or wound. HyperTET® may also be used to treat tetanus in patients who already have tetanus.

How does HyperTET® work?

HyperTET® provides immediate protection against tetanus. Vaccines work by stimulating your immune system to produce antibodies against a particular disease. Because vaccines require this immune response, they take time to work and are not immediately effective. HyperTET® is made from the blood of people who have already been vaccinated against tetanus and therefore already contains antitoxins to fight a tetanus infection. It starts working immediately after being injected and helps to protect you from getting tetanus in situations where you are unsure about your immunization history, have had less than 3 doses of tetanus vaccine, or if you have an immune deficiency.

What are the ingredients in HyperTET®?

Medicinal ingredients: Human Tetanus Immunoglobulin

Non-medicinal ingredients: Glycine

HyperTET® comes in the following dosage forms:

Single use pre-filled syringes with a minimum potency of 250 antitoxin units in 1 mL (AU/mL)

Do not use HyperTET® if:

Serious Warnings and Precautions

  • Your doctor should discuss the risks and benefits of this product with you before prescribing or administering it to you.
  • This product must only be administered by intramuscular injection. It must not be given intravenously.
  • This product is made from human plasma may theoretically contain infectious agents such as viruses that can cause disease
  • you are allergic to this drug or to any ingredient in the formulation or component of the container.
  • you have any bleeding disorder that would make it unsafe for you to be given an injection into the muscles.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take HyperTET®. Talk about any health conditions or problems you may have, including if you:

  • have previously had a reaction to any immunoglobulin product like HyperTET® and/or if you have an immunoglobulin A (IgA) deficiency
  • have been diagnosed with thrombocytopenia or any other bleeding disorder
  • are pregnant or breastfeeding

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with HyperTET®:

Certain types of vaccines such as measles, mumps, polio or rubella. HyperTET® could interfere with the effectiveness of certain vaccines, and you should avoid being vaccinated with these until 3 months after your treatment with HyperTET®.

How to take HyperTET®:

Your healthcare professional will administer HyperTET®. It should be given as an intramuscular injection into the upper part of the arm, or the side of the thigh.

Usual dose:

The recommended dose of HyperTET® is 250 antitoxin units in 1 mL (i.e. one pre-filled syringe).

Overdose:

There is no data regarding what to expect in case of a HyperTET® overdose, although experience with similar products suggests that the only issues might include pain and tenderness at the injection site.

What are possible side effects from using HyperTET®?

These are not all the possible side effects you may have when taking HyperTET®. If you experience any side effects not listed here, tell your healthcare professional.

The most common side effects that have been reported following use of HyperTET®, include pain or soreness at the site of injection, slight fever, rash, and itching. There have been rare reports of a serious allergic reaction called anaphylaxis. Symptoms of an allergic or hypersensitivity reaction can include dizziness, numbness or tingling, rash, flushing, difficulty breathing, rapid heart rate, pain in the mouth and throat, excessive sweating, and reddening of the skin (flushing). If you think you are having an allergic or hypersensitivity reaction, tell your doctor immediately.

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

  • Visiting the Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html) for information on how to report online, by mail or by fax; or
  • Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

HyperTET® (Tetanus Immunoglobulin [Human]) should be stored at 2 - 8°C, and should never be frozen.

Keep out of reach and sight of children.

If you want more information about HyperTET®:

  • Talk to your healthcare professional
  • Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html; or by calling 1-866-482-5226.

Last Revised: September 8, 2021

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02520087

Revision date stated in the text: September 8, 2021

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Hypertet

DIN 02520087
Schedule(s) SCHEDULE D
Active ingredient(s) Tetanus immunoglobulin (human) 250 UNIT
Dosage form(s) Solution
Route(s) of administration Intramuscular
Drug class (WHO ATC)
  1. J Antiinfectives for systemic use
    1. J06 Immune sera and immunoglobulins
      1. J06B Immunoglobulins
        1. J06BB Specific immunoglobulins
          1. J06BB02 Tetanus immunoglobulin
Company GRIFOLS THERAPEUTICS LLC
Current status Marketed
Current status date December 13, 2021

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.